ARTICLE | Clinical News
RSR13: Began Phase Ib/II trial
January 22, 2001 8:00 AM UTC
Allos Therapeutics Inc. (ALTH), Denver, Colo. Product: RSR13 Business: Cancer Therapeutic category: Adjunct, Oxygenation Target: Hemoglobin Description: A 2-(aryloxy)-2-alkanoic acid allosteric hemogl...